Motley Fool 10/11 "There is a clear increase in lung function when used together." *link*
Motley Fool 10/11 By: Davis Williamson
Vertex Pharmaceuticals (Nasdaq: VRTX ) presented more Kalydeco and VX-809 trial results battling cystic fibrosis, and there were no negative surprises.There is a clear increase in lung function when used together.
If you want a legit reason why the stock is falling, it's more than likely because after not presenting 100% accurate data last time, investor condfidence in VRTX is lacking this time around. If you want a reason that's not so legit, think hedgefunds, bear raids, and HFT